Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poliovirus receptor-related 2 protein (CD112)
- Target
- CD112
- Molecular classification
- Cell adhesion molecule, Immunoglobulin superfamily, Type I transmembrane glycoprotein, Receptor
01
Overview
CD112, also known as poliovirus receptor-related 2 protein or nectin-2, is a cell surface adhesion molecule belonging to the immunoglobulin superfamily and functions as a type I transmembrane glycoprotein. It is broadly expressed in epithelial, endothelial, neuronal, and hematopoietic cells. CD112 plays major roles in cell–cell adhesion (especially at adherent junctions), immune regulation as a ligand for immune receptors like TIGIT, CD112R (PVRIG), and DNAM-1 (CD226), and as a mediator of viral entry for certain herpesviruses. High expression or altered regulation of CD112 has been linked to tumor progression, metastasis, and poor prognosis in various cancers. CD112 is considered a novel target for immune checkpoint inhibition strategies in cancer immunotherapy.
- Other names
- Nectin-2PVRL2HveBPRR2PVRR2
02
Mechanism of action
Modulation of antitumor immunity by blocking CD112–TIGIT or CD112–CD112R interactions, which relieves immune inhibition and enhances cytotoxic T/NK cell responses
03
Biological functions
Cell adhesionImmune response (specifically immunoregulation by interaction with DNAM-1 and TIGIT)Signal transductionViral entry (herpesvirus mediation)
04
Disease associations
Cancer (tumor progression and immune evasion)Infection (herpesvirus entry and cell-to-cell spread)Potential role in autoimmune disease (via modulation of NK and cytotoxic T cell activity)
05
Safety considerations
Potential for immune-related adverse events due to enhanced immune activation when CD112-mediated checkpoints are blockedPossible off-tumor effects because CD112 is expressed in normal epithelial, endothelial, neuronal, and hematopoietic cells
06
Interacting drugs
No small-molecule drugs directly targeting CD112 approved; therapeutic antibodies or immune checkpoint inhibitors (e.g., targeting TIGIT-CD112 axis) are in development as immune modulators
07
Biomarkers
CD112 expression level as a biomarker for prognosis in cancers such as bladder urothelial carcinoma, ovarian cancer, and acute myeloid leukemia
Beyond the preview
Go deeper on Poliovirus receptor-related 2 protein (CD112).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Poliovirus receptor-related 2 protein (CD112).